Company Profile - NovoCure Ltd

Introduction

NovoCure Ltd (NovoCure) is focused on the development and commercialization of novel delivery systems for the treatment of cancers of brain, thoracic and abdomen. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division of solid tumor cancer cells. The company markets TTF-based delivery systems: Optune Lua for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both the products are indicated in combination with standard chemotherapies. Its product development and clinical programs strive to improve the survival of patients suffering from pancreatic cancer, brain metastases, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer, among others. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.